Evelo Biosciences Inc expected to post a loss of 28 cents a share - Earnings Preview

Evelo Biosciences

14/03/2023 12:45

* Evelo Biosciences Inc  EVLO.OQ   EVLO.O  is expected
to show no
change in quarterly revenue when it reports  results on March
16. 
    * 
    * ​Refinitiv's mean analyst estimate for Evelo Biosciences
Inc is
for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evelo
Biosciences
Inc is $2.5​, above​ its last closing price of $0.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.35       -0.33      -0.28     Beat    16.4
 Jun. 30 2022  -0.44       -0.43      -0.40     Beat    7.7
 Mar. 31 2022  -0.58       -0.58      -0.56     Beat    3.8​
 Dec. 31 2021              -0.61      -0.54     Beat    11.5
 ​​Sep.        -0.55       -0.54      -0.63     Missed  -16.7
 30 2021                                                
 Jun. 30 2021  -0.53       -0.54      -0.53     Beat    2.2​
 Mar. 31 2021  -0.51       -0.51      -0.55     Missed  -8.7
 Dec. 31 2020  -0.59       -0.53      -0.62     Missed  -17.5
 This summary was machine generated March 14 at 12:45 GMT.  All
figures in US dollars  unless otherwise stated